Abstract

Antipsychotics (APs) reduce abnormal neurotransmitter activity and treat mental conditions. However, APs can cause withdrawal symptoms, which can disrupt normal physiology. This research aimed to evaluate the APs' withdrawal symptoms and their evidence-based management. In the current review, forty-six papers were included after careful evaluation. All studies comparing the withdrawal symptoms between typical and atypical APs were included, while those focusing solely on safety were excluded. Quality and strength of evidence were also evaluated by standardised criteria. Abrupt discontinuation of typical APs results in dopaminergic rebound, causing motor symptoms. The aberrant discontinuation of atypical APs results in rebounds of dopaminergic, serotonergic, and cholinergic systems, leading to emotional dysregulation. Withdrawal symptoms must be managed by considering individual drug mechanisms as well as the demographics of patients. Clozapine withdrawal is associated with fewer side effects when tapered gradually over six months; risperidone discontinuation requires careful monitoring for dose-dependent extrapyramidal symptoms. Adolescents using olanzapine exhibit higher withdrawal-related morbidity compared to other age groups. Prolonged tapering of quetiapine has been shown to effectively mitigate withdrawal symptoms. Patients discontinuing aripiprazole experience mood swings due to its partial agonist effects on dopamine receptors; abrupt discontinuation of ziprasidone can lead to rebound psychosis and increased anxiety. The discontinuation of APs over a prolonged period shows improved patient outcomes; however, the period for discontinuation should be tailored to the individual patient's needs and the medication used. A holistic approach to tapered discontinuation can improve medical and psychosocial outcomes.

Keywords: Typical-antipsychotics, atypical-antipsychotics, withdrawal, symptoms, dopamine-receptor, serotonin-receptor.

INTRODUCTION

Antipsychotics (APs) are indicated to treat psychotic illnesses; these illnesses are usually accompanied by hallucinations and delusions [1, 2]. In addition, antipsychotic drugs are also indicated to treat a wide range of other mental conditions, including agitation in neurodegenerative disorders, psychotic depression, and bipolar affective disorder [3, 4]. According to research analysis, around 75% of patients discontinue the use of their antipsychotic medications within 18 months [5]. However, to control side effects, people usually self-regulate and alter the doses of their antipsychotic medications. Furthermore, antipsychotic drugs are categorised into two classes: typical(e.g., chlorpromazine, trifluoperazine, thioridazine, perphenazine, fluphenazine, thiothixene, haloperidol, molindone, loxapine) and atypical (e.g., clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, asenapine, iloperidone, lurasidone). Typical APs block dopamine, while atypical ones have effects on both serotonin and dopamine, but the effects of dopamine are not as strong as those of typical antipsychotics [6, 7]. Except for clozapine, it seems appropriate to administer typical or atypical antipsychotics in the treatment of acute psychoses as well as in the maintenance treatment of schizoaffective and schizophrenia disorders [5]. The first generation (typical) APs do better at combating the more simplistic schizophrenia, more specifically delusions and hallucinations [7]. In opposition, the second generation (atypical) APs minimise relapses and address positive and negative symptoms of the illness, such as ambivalence and withdrawal [6, 7].

Unfortunately, the withdrawal symptoms can often resemble a worsening of the underlying mental condition when antipsychotics are withdrawn [5]. There are several examples of such symptoms, including autonomic instability, motor abnormalities, and rebound psychosis [6]. There are claims that about 40% of patients experience antipsychotic withdrawal symptoms, which underscores therapeutic or non-therapeutic understanding and management of these symptoms [5]. Akathisia and withdrawal dyskinesia are the motor symptoms that are prominent in the withdrawal pattern of common typical antipsychotics [7]. Research suggested that in the case of abrupt cessation of drugs like typical antipsychotic drugs like fluphenazine or haloperidol, there could be a large dopaminergic surge, resulting in uncontainable movements and a reinstatement of psychoses [8]. Apart from the withdrawal phase, symptoms like tachycardia, sweats and gastrointestinal upset are also apparent [9].

Although second-generation APs are more effective than first-generation APs, they are less likely to result in involuntary changes as well as side effects (especially motor ones) [8, 10]. According to one study, upon withdrawal, these drugs could cause anti-cholinergic rebound, insomnia and alterations of mood stability [8]. For example, salivation, diarrhea and extreme levels of anxiety render the sudden discontinuation of clozapine [9]. Similarly, APs that have high serotonergic activity, such as atypical antipsychotic olanzapine, are more likely to result in poor control of emotions and increased frequency of depressive episodes after cessation [10].

On the contrary, first-generation (typical) antipsychotic medications are most effective when they block the dopamine (D2) receptors in the brain's basal ganglia [9]. Ultimately, long-term therapy leads to dopamine receptor upregulation when the brain develops more dopamine receptors or makes existing ones more effective in response to reduced dopamine function [11]. It is analysed that dopamine enables excess transmission of the sensitive receptors when medication is stopped, resulting in dopaminergic hyperactivity [12]. The use of atypical antipsychotics is a classical explanation of the tolerance phenomenon, as medications lose effectiveness over time [13]. Withdrawal from atypical APs involves more complex interplay between the dopaminergic, serotonergic and cholinergic systems that results in emotional and autonomic dysfunction [14]. In contrast, typical AP withdrawal primarily manifests as dyskinesia and delusions due to dopaminergic action [11].

Therefore, designing individualised cessation protocols, a cross-comparative study is required owing to the different antipsychotic-type characteristics and withdrawal symptoms. Hence, the current review aimed to expand on the literature on the withdrawal symptoms of APs and provided the necessary differences that must be considered concerning their pathogenesis, clinical course, manifestations and therapy. The review may provide practitioners with useful recommendations supported by the findings of the latest clinical studies, which hopefully would qualify the withdrawal of antipsychotics as a safer and more effective procedure.

METHODOLOGY

Study Design: This article examined the differences in withdrawal symptoms between typical and atypical APs using a narrative review methodology. The study thoroughly compares the withdrawal symptoms of these two classes of medications by synthesising results from recent observational studies and clinical trials.

Search Strategy: This study used PubMed, BioMed Central, PsycINFO, National Database of Indian Medical Journals, African Journals Online (AJOL) and Google Scholar for searching the literature. Typical APs discontinuation, typical and atypical APs withdrawal, antipsychotic withdrawal symptoms and antipsychotic cessation are the keywords utilised in this literature search. To guarantee that current APs and pertinent withdrawal information are included, the search concentrated on papers published in peer- reviewed journals within the last 15 years (2010 to 2024). A structured literature search was performed to retrieve the relevant studies for preparation of this manuscript. Out of total 77 identified record, finally 24 papers were studied for producing this narrative review (Fig. 1) [15].

Inclusion and Exclusion Criteria: Studies comparing withdrawal symptoms in patients stopping conventional and atypical APs, clinical research on humans, observational studies, case studies, and meta-analyses about antipsychotic withdrawal symptoms were included. However, research that concentrates on antipsychotic safety or efficacy but ignores withdrawal symptoms is excluded. Papers that focus on experimental APs but are not authorised for clinical use or animal research are also excluded from the study. Those articles or research analyses written in a language other than English were also excluded.

Study Selection and Data Extraction: The studies were selected based on selection criteria and evaluated for eligibility, and ultimately added to this article. Two separate reviewers screened all identified articles' titles and abstracts. Potentially eligible studies' full texts were retrieved and thoroughly evaluated.

Data Compilation and Analysis: To evaluate withdrawal symptoms between typical and atypical APs, the retrieved data were combined. The main conclusions are described, such as the kinds of withdrawal symptoms, how long they last and how they affect patients. Quality of the literature was determined by GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria [16].

FINDINGS AND DISCUSSION

Table 1 summarises the differences in withdrawal symptoms between typical and atypical APs. Each study was evaluated for its objectives and outcomes [17-30]. Table 2 summarises the withdrawal strategies based on the literature evaluated.

Antipsychotics (APs) have withdrawal symptoms when discontinued, and these withdrawal symptoms vary between typical and atypical APs. The abrupt discontinuation of typical APs resulted in a dopaminergic rebound, causing motor symptoms like dyskinesia and akathisia along with psychotic relapses resembling the primary illness [31]. However, the aberrant discontinuation of atypical APs resulted in rebounds of dopaminergic, serotonergic, and cholinergic systems [32]. Thus, the spectrum of withdrawal symptoms is broader in patients treated with atypical APs and symptoms included mood dysregulation, sweating, gastrointestinal upset, hyper salivation and increased anxiety [33].

Although atypical APs have more withdrawal symptoms, on the other hand, they have superior safety and efficacy profiles compared to typical APs [7]. This review presented strategies to manage the withdrawal symptoms of atypical APs effectively. For instance, studies have shown that extending the withdrawal period over one month reduced the risks of primary symptoms relapse and neuroadaptive responses [34, 35]. Additionally, the management of withdrawal symptoms ought to be differentiated according to the specific medications being used. For instance, the hazards associated with withdrawal from clozapine are negligible when the medication is stopped gradually over six months [36, 37]. Risperidone is associated with dose-dependent extra-pyramidal symptoms, necessitating thorough patient screening for motor symptoms throughout the cessation process [31]. These findings are consistent with another review article written by Horowitz et al. [38]. To minimise withdrawal symptoms and ensure long-term stability for patients, it is essential to develop discontinuation protocols for certain Aps [39, 40].

Furthermore, managing withdrawal symptoms varied according to demographic parameters [41]. For instance, Merino et al. reported atypical APs misuse and withdrawal-related morbidity linked to drugs like quetiapine and olanzapine among adolescents [18]. Therefore, practitioners must carefully consider the sensitivity of treatment plans for withdrawal symptoms management as per patient age [42]. The decision to stop APs could add to the chances of relapse; this could be associated with dopaminergic hypersensitivity that remained even after the treatment has been withdrawn [43]. Therefore, a gradual tapering of APs would be beneficial in reversing the dependency and reducing the possibility of a relapse after stopping the medications [44, 45].

In addition, based on animal studies, observations of tardive dyskinesia, and the temporal clustering of relapse events, there is a risk of transition to the chronic state that remains after stopping the medication [41]. However, atypical APs do not affect tardive dyskinesia and the temporal clustering in drug-naive patients. Atypical drugs increase temporal clustering volume in the thalamus and cortex [46]. This suggested that structural changes from schizophrenia may be reversed with atypical drugs. Due to this reason, in treating schizophrenia, a significant expectation has been raised for atypical APs over typical APs [47]. According to one study, 585 people experienced withdrawal antipsychotic symptoms; of which 72% of participants reported anxiety, anxiousness, headaches, nausea, shivering, and other symptoms, which are medically referred to as classical withdrawal syndrome [19]. An additional 52% of the same patients later indicated that the tremors had started, which made their withdrawal worse [19]. Furthermore, 23% had waited at least a year before quitting entirely, and 26% had tried to quit for four or more years [19]. When asked an open- ended question about side effects, 73% of participants said they had experienced insomnia and anxiety or panic attacks [19]. 26% said they had more energy and were thinking more clearly, while 18% said they were experiencing anxiety or panic attacks [19].

There have been limited clinical trials exploring the withdrawal dynamics of APs. The available studies predominantly focused on short-term withdrawal outcomes, while limited exploration of long-term implications exists. Additionally, the evaluation of the psychological impact of withdrawal symptoms, such as emotional dysregulation, with the use of atypical APs has been scarce.

CONCLUSION

The withdrawal symptoms of typical and atypical APs have distinct mechanisms resulting in varied neuroadaptive responses as well as post-withdrawal complications. Atypical APs have higher emotional dysregulation post-withdrawal, while typical APs have higher motor symptoms. Discontinuation of APs over a prolonged period has shown improved patient outcomes; however, the period for discontinuation should be tailored to the individual patient's needs and the medication used. A holistic approach to tapered discontinuation can improve medical and psychosocial outcomes among patients using APs.

RECOMMENDATIONS

Future research should explore the long-term management of withdrawal symptoms from antipsychotic drugs. Furthermore, clinical trials should explore the integration of adjunctive therapies to manage withdrawal symptoms effectively. Clinical practitioners should offer tailored medication management during discontinuation by considering the patient's medication history, underlying mental health conditions and the specific withdrawal profiles of the APs being used.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

AUTHORS' CONTRIBUTIONS

Conception and design; collection and assembly of data: Muhammad Usama Tahir

REFERENCES

1. González-Rodríguez A, Monreal JA, Natividad M, Seeman MV. Seventy years of treating delusional disorder with antipsychotics: A historical perspective. Biomedicines 2022; 10(12): 3281. DOI: https://doi.org/10.3390/biomedicines10123281 PMID: 36552037

2. Harrow M, Jobe TH, Tong L. Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders. Psychol Med 2022; 52(13): 2681-91. DOI: https://doi.org/10.1017/s0033291720004778 PMID: 33550993

3. Carrarini C, Russo M, Dono F, Barbone F, Rispoli MG, Ferri L, et al. Agitation and dementia: prevention and treatment strategies in acute and chronic conditions. Front Neurol 2021; 12: 644317. DOI: https://doi.org/10.3389/fneur.2021.644317 PMID: 33935943

4. Seritan AL. Advances in the diagnosis and management of psychotic symptoms in neurodegenerative diseases: a narrative review. J Geriatr Psychiatry Neurol 2023; 36(6): 435-60. DOI: https://doi.org/10.1177/08919887231164357 PMID: 36941085

5. Malla A, Iyer SN, Joober R, Rangaswamy T, Ramachandran P, Schmitz N, et al. An observational study of antipsychotic medication discontinuation in first-episode psychosis: clinical and functional outcomes. Soc Psychiatry Psychiatr Epidemiol 2022; 57(7): 1329-40. DOI: https://doi.org/10.1007/s00127-022-02230-0 PMID: 35041015

6. Grinchii D, Dremencov E. Mechanism of action of atypical antipsychotic drugs in mood disorders. Int J Mol Sci 2020; 21(24): 9532. DOI: https://doi.org/10.3390/ijms21249532 PMID: 33333774

7. Meltzer HY, Gadaleta E. Contrasting typical and atypical antipsychotic drugs. Focus (Am Psychiatr Publ) 2021; 19(1): 3-13. DOI: https://doi.org/10.1176/appi.focus.20200051 PMID: 34483761

8. Leucht S, Huhn M, Davis JM. Should 'typical', first-generation antipsychotics no longer be generally used in the treatment of schizophrenia? Eur Arch Psychiatry Clin Neurosci 2021; 271(9): 1411–3. DOI: https://doi.org/10.1007/s00406-021-01335-y PMID: 34586466

9. Uchida H, Kim E, Jarskog LF, Fleischhacker WW, Remington G, Lieberman JA. Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics). In: Tasman A, Riba MB, Alarcón RD, Alfonso CA, Kanba S, Lecic-Tosevski D, Ndetei DM, Ng CH, Schulze TG Eds Tasman's Psychiatry. 5th ed. Cham, Switzerland: Springer 2023: pp. 4123-80.

10. Fabrazzo M, Cipolla S, Camerlengo A, Perris F, Catapano F. Second-generation antipsychotics' effectiveness and tolerability: a review of real-world studies in patients with schizophrenia and related disorders. J Clin Med 2022; 11(15): 4530. DOI: https://doi.org/10.3390/jcm11154530 PMID: 35956145

11. Speranza L, Di Porzio U, Viggiano D, de Donato A, Volpicelli F. Dopamine: the neuromodulator of long-term synaptic plasticity, reward and movement control. Cells 2021; 10(4): 735. DOI: https://doi.org/10.3390/cells10040735 PMID: 33810328

12. Gomes FV, Grace AA. Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention. Int J Mol Sci 2021; 22(9): 4467. DOI: https://doi.org/10.3390/ijms22094467 PMID: 33922888

13. Aringhieri S, Carli M, Scarselli M. Atypical Antipsychotics. In: Offermanns S, Rosenthal W, Eds. Encyclopedia of Molecular Pharmacology. 3rd ed. Cham, Switzerland: Springer 2022; pp. 275-81.

14. Mukherjee S, Skrede S, Milbank E, Andriantsitohaina R, López M, Fernø J. Understanding the effects of antipsychotics on appetite control. Front Nutr 2022; 8: 815456. DOI: https://doi.org/10.3389/fnut.2021.815456 PMID: 35047549

15. Harrison H, Griffin SJ, Kuhn I, Usher-Smith JA. Software tools to support title and abstract screening for systematic reviews in healthcare: an evaluation. BMC Med Res Methodol 2020; 20(1): 7. DOI: https://doi.org/10.1186/s12874-020-0897-3 PMID: 31931747

16. Schwingshackl L, Rüschemeyer G, Meerpohl JJ. How to interpret the certainty of evidence based on GRADE (Grading of Recommendations, Assessment, Development and Evaluation). Urologe A 2021; 60(4): 444-54. DOI: https://doi.org/10.1007/s00120-021-01471-2 PMID: 33620513

17. de Kuijper G, de Haan J, Deb S, Shankar R. Withdrawing antipsychotics for challenging behaviours in adults with intellectual disabilities: experiences and views of prescribers. Int J Environ Res Public Health 2022; 19(24): 17095. DOI: https://doi.org/10.3390/ijerph192417095 PMID: 36554973

18. Merino D, Gérard AO, Destere A, Askenazy F, Drici M-D, Thümmler S. Antipsychotic abuse, dependence, and withdrawal in the pediatric population: a real-world disproportionality analysis. Biomedicines 2022; 10(11): 2972. DOI: https://doi.org/10.3390/biomedicines10112972 PMID: 36428541

19. Read J. The experiences of 585 people when they tried to withdraw from antipsychotic drugs. Addict Behav Rep 2022;15: 100421. DOI: https://doi.org/10.1016/j.abrep.2022.100421 PMID: 35434245

20. Larsen-Barr M, Seymour F. Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication. Ther Adv Psychopharmacol 2021; 11(1): 2045125321989133. DOI: https://doi.org/10.1177/2045125321989133 PMID: 33796264

21. Deb S, Limbu B, Unwin GL, Weaver T. The use of medication for challenging behaviors in people with intellectual disabilities: the direct care providers' Perspective. J Ment Health Res Intellect Disabil 2023; 16(3): 253-74. DOI: https://doi.org/10.1080/19315864.2023.2192691

22. Chiappini S, Schifano F, Corkery JM, Guirguis A. Focus on clozapine withdrawal-and misuse-related cases as reported to the European Medicines Agency (EMA) pharmacovigilance database. Brain Sci 2020; 10(2): 105. DOI: https://doi.org/10.3390/brainsci10020105 PMID: 32079135

23. Kleijwegt B, Pruijssers A, de Jong‐Bakker L, de Haan K, van Os‐Medendorp H, van Meijel B. Support staff's perceptions of discontinuing antipsychotics in people with intellectual disabilities in residential care: A mixed‐method study. J Appl Res Intellect Disabil 2019; 32(4): 861-70. DOI: https://doi.org/10.1111/jar.12577 PMID: 30790388

24. Taipale H, Lähteenvuo M, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J. Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia. Schizophr Bull 2021; 47(1): 23-30. DOI: https://doi.org/10.1093/schbul/sbaa111 PMID: 33428766

25. Emsley R, Nuamah I, Gopal S, Hough D, Fleischhacker WW. Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs. illness recurrence: a post hoc analysis of a randomized placebo-controlled study. J Clin Psychiatry 2018; 79(4): 17m11874. DOI: https://doi.org/10.4088/jcp.17m11874 PMID: 29924507

26. Ostrow L, Jessell L, Hurd M, Darrow SM, Cohen D. Discontinuing psychiatric medications: a survey of long-term users. Psychiatric Serv 2017; 68(12): 1232-8. DOI: https://doi.org/10.1176/appi.ps.201700070 PMID: 28712356

27. Sarma S, Chetia D, Raha B, Agarwal G. Clozapine withdrawal emergent dystonia, oculogyric crisis and rebound psychosis in a single patient. Ther Adv Psychopharmacol 2015; 6(2): 145-6. DOI: https://doi.org/10.1177/2045125315591928 PMID: 27141293

28. Landolt K, Rössler W, Ajdacic-Gross V, Derks EM, Libiger J, Kahn RS, et al. Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST). Schizoph Res 2016; 172(1-3): 145-51. DOI: https://doi.org/10.1016/j.schres.2016.01.046 PMID: 26922655

29. Azermai M, Petrovic M, Engelborghs S, Elseviers M, Van der Mussele S, Debruyne H, et al. The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: a pilot study. Aging Ment Health 2013; 17(1): 125-32. DOI: https://doi.org/10.1080/13607863.2012.717255 PMID: 22928861

30. Cerovecki A, Musil R, Klimke A, Seemüller F, Haen E, Schennach R, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS drugs 2013; 27(7): 545-72. DOI: https://doi.org/10.1007/s40263-013-0079-5 PMID: 23821039

31. Brandt L, Bschor T, Henssler J, Müller M, Hasan A, Heinz A, et al. Antipsychotic withdrawal symptoms: a systematic review and meta-analysis. Front Psychiatry 2020; 11: 569912. DOI: https://doi.org/10.3389/fpsyt.2020.569912 PMID: 33132934

32. Beumer S, Hamers P, Oppewal A, Maes-Festen D. Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo- controlled randomised trial. BMC Psychiatry 2021; 21(1): 439. DOI: https://doi.org/10.1186/s12888-021-03437-2 PMID: 34488701

33. Pourhamzeh M, Moravej FG, Arabi M, Shahriari E, Mehrabi S, Ward R, et al. The roles of serotonin in neuropsychiatric disorders. Cell Mol Neurobiol 2022; 42(6): 1671-92. DOI: https://doi.org/10.1007/s10571-021-01064-9 PMID: 33651238

34. Larsen-Barr M, Seymour F, Read J, Gibson K. Attempting to discontinue antipsychotic medication: withdrawal methods, relapse and success. Psychiatry Res 2018; 270: 365-74. DOI: https://doi.org/10.1016/j.psychres.2018.10.001 PMID: 30300866

35. Hegde AR, Paul M, Kumbham S, Roy AA, Ahmad SF, Parekh H, et al. Ameliorative anticancer effect of dendrimeric peptide modified liposomes of letrozole: In vitro and in vivo performance evaluations. Int J Pharm 2023; 648: 123582. DOI: https://doi.org/10.1016/j.ijpharm.2023.123582 PMID: 37940082

36. Belteczki Z, Ujvari J, Dome P. Clozapine withdrawal-induced malignant catatonia or neuroleptic malignant syndrome: a case report and a brief review of the literature. Clin Neuropharmacol 2021; 44(4): 148-53. DOI: https://doi.org/10.1097/wnf.0000000000000462 PMID: 34132673

37. Blackman G, Oloyede E. Clozapine discontinuation withdrawal symptoms in schizophrenia. Ther Adv Psychopharmacol 2021; 11: 20451253211032053. DOI: https://doi.org/10.1177/20451253211032053 PMID: 34552710

38. Horowitz MA, Framer A, Hengartner MP, Sørensen A, Taylor D. Estimating risk of antidepressant withdrawal from a review of published data. CNS Drugs 2023; 37(2): 143-57. DOI: https://doi.org/10.1007/s40263-022-00960-y PMID: 36513909

39. Vinkers CH, Kupka RW, Penninx BW, Ruhé HG, van Gaalen JM, van Haaren PC, et al. Discontinuation of psychotropic medication: a synthesis of evidence across medication classes. Mol Psychiatry 2024; 29(8): 2575–86. DOI: https://doi.org/10.1038/s41380-024-02445-4 PMID: 38503923

40. Stürup AE, Hjorthøj C, Albert N, Dolmer S, Birk M, Ebdrup BH, et al. Tapered discontinuation vs. maintenance therapy of antipsychotic medication in patients with first-episode schizophrenia: Obstacles, findings, and lessons learned in the terminated randomized clinical trial TAILOR. Front Psychiatry 2022; 13(1): 910703. DOI: https://doi.org/10.3389/fpsyt.2022.910703 PMID: 35935409

41. Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D. A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophr Bull 2021; 47(4): 1116-29. DOI: https://doi.org/10.1093/schbul/sbab017 PMID: 33754644

42. Tuck J. Overview of the therapeutic use of medicines in mental health. In: Trenoweth S, Ed. Understanding Mental Health Practice for Adult Nursing Students. 1st ed CA, USA: SAGE 2022; pp. 107-35

43. Kimura H, Kanahara N, Iyo M. Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity. Behav Brain Res 2021; 403(1): 113126. DOI: https://doi.org/10.1016/j.bbr.2021.113126 PMID: 33460681

44. Gøtzsche PC, Demasi M. Interventions to help patients withdraw from depression drugs: A systematic review. Int J Risk Saf Med 2024; 35(2): 103-16. DOI: https://doi.org/10.3233/jrs-230011 PMID: 37718853

45. Eserian JK, Blanco VP, Mercuri LP, do Rosario Matos J, Galduróz JCF. Current strategies for tapering psychiatric drugs: differing recommendations, impractical doses, and other barriers. Psychiatry Res 2023; 329(1): 115537. DOI: https://doi.org/10.1016/j.psychres.2023.115537 PMID: 37837810

46. Turkheimer FE, Selvaggi P, Mehta MA, Veronese M, Zelaya F, Dazzan P, et al. Normalizing the abnormal: do antipsychotic drugs push the cortex into an unsustainable metabolic envelope? Schizophrenia Bulletin 2020; 46(3): 484-95. DOI: https://doi.org/10.1093/schbul/sbz119 PMID: 31755955

47. Remington G, Hahn MK, Agarwal SM, Chintoh A, Agid O. Schizophrenia: antipsychotics and drug development. Behav Brain Res 2021; 414(1): 113507. DOI: https://doi.org/10.1016/j.bbr.2021.113507 PMID: 34352293